00882 TIANJIN DEV
- 1.960
- 0.0000.00%
TIANJIN DEV News
TIANJIN DEV (00882.HK): Xia Binhui has been appointed as Executive Director and Deputy General Manager.
Gelonghui reported on December 30 that TIANJIN DEV (00882.HK) announced that the Board of Directors has appointed Xia Binhui as the company's executive director and deputy general manager, effective from December 30, 2024.
TIANJIN DEV (00882): Xia Binhui has been appointed as Executive Director.
TIANJIN DEV (00882) announced that Xia Binhui has been appointed as the company's executive Director and vice general manager, starting from 2024...
Tianjin Development Subsidiary to Repurchase Shares, Grant Shares Under Share Award Scheme
Tianjin DEV (00882.HK) subsidiary Tianjin Lisheng Pharmaceutical plans to repurchase shares and adopt a stock incentive plan.
On December 20, Grizzly Holdings announced that TIANJIN DEV (00882.HK) has approved a share buyback plan at the Board of Directors of Tianjin Lisheng Pharmaceutical (a non-wholly-owned subsidiary indirectly listed on the Shenzhen Stock Exchange) on December 20, 2024. Accordingly, starting from December 21, 2024, within a period of twelve months, Tianjin Lisheng Pharmaceutical is allowed to repurchase its ordinary shares through centralized bidding on the Shenzhen Stock Exchange at the current market price, with a total amount not less than 76.5 million yuan and not exceeding 0.153 billion yuan. The Board of Directors of Tianjin Lisheng Pharmaceutical recommends that this be approved by its Shareholders at the Shareholders' meeting.
Tianjin Development Renews Service Contracts With Associate
Tianjin dev: Tianjin Lisheng Pharmaceutical's net income attributable to the parent company in the first three quarters decreased by 50.6% to 0.169 billion yuan.
Tianjin dev (00882) announced that tianjin lisheng pharmaceutical, an indirectly wholly-owned subsidiary, achieved total operating income of 1.024 billion yuan (RMB, the same below) for the nine months ended September 30, 2024, a year-on-year increase of 12.3%; net income attributable to the owners of the parent company was 0.169 billion yuan, a year-on-year decrease of 50.6%; and basic earnings per share was 0.66 yuan.
Tianjin DEV (00882): Tianjin Lisheng Pharmaceutical's net income attributable to mother for the first three quarters was 0.169 billion yuan.
tianjin dev (00882) announced that its indirect non-wholly-owned subsidiary tianjin lisheng pharmaceutical as at 3 September 2024...
TIANJIN DEV: Unaudited Financial Results for the nine months ended 30 September 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Tianjin Lisheng Invests 210 Million Yuan in China Bohai Bank's Structured Deposit
tianjin dev (00882.HK) subsidiary subscribed 0.21 billion yuan for another structured deposit.
Grill Lockmate September 26th Tianjin Dev (00882.HK) announced that due to the expiration of the previous structured deposits, on September 26, 2024, the company's indirectly controlled non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical and CBHB signed a third CBHB wealth management agreement, subscribing to another structured deposit with a principal amount of RMB 0.21 billion.
TIANJIN DEV: 2024 Interim Report
Tianjin Development Holdings Books Lower Profit, Revenue in H1
TIANJIN DEV To Go Ex-Dividend On September 23rd, 2024 With 0.0518 HKD Dividend Per Share
August 29th (Beijing Time) - $TIANJIN DEV(00882.HK)$ is trading ex-dividend on September 23rd, 2024.Shareholders of record on September 24th, 2024 will receive 0.0518 HKD dividend per share on
tianjin dev (00882.HK) has a net profit of approximately 0.288 billion Hong Kong dollars for the interim period, with an interim dividend of 5.18 Hong Kong cents.
Great Connection August 29th, Tianjin Dev (00882.HK) announced that for the six months ended June 30, 2024, the company's income was approximately HK$1,820,260,000 (same period last year: HK$1,830,477,000). The attributable profit to owners of the company was approximately HK$288,077,000 (same period last year: HK$371,509,000). Basic earnings per share were 26.85 HK cents, with an interim dividend of 5.18 HK cents per share (same period last year: 3.45 HK cents per share).
TIANJIN DEV: Announcement of Interim Results for the six months ended 30 June 2024
Tianjin Lisheng Pharmaceutical's H1 Attributable Profit, Revenue Grow
Tianjin Dev (00882.HK): Tianjin Lisheng Pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.
Tianjin Development (00882.HK) announced that Tianjin Lisheng Pharmaceutical (002393.SZ) achieved revenue of 0.745 billion yuan (RMB) in the first half of 2024, a year-on-year growth of 13.25%; the net income attributable to Lisheng Pharmaceutical shareholders was 0.102 billion yuan, a year-on-year growth of 13.50%; the basic earnings per share was 0.40 yuan.
TIANJIN DEV: Unaudited Financial Results for the six months ended 30 June 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Board of directors of Tianjin Dev (00882.HK) held a meeting on August 29 to consider and approve the mid-term performance.
Tianjin Dev (00882.HK) announced that it will hold a board of directors meeting on Thursday, August 29, 2024 to consider and approve, among other matters, the announcement of the Company and its subsidiaries' interim results for the six months ended June 30, 2024, and to consider the distribution of interim dividends (if any).
TIANJIN DEV: Date of Board Meeting
No Data
